Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Preferred Stock Liabilities (2019 - 2020)

Historic Preferred Stock Liabilities for Lyell Immunopharma (LYEL) over the last 2 years, with Q4 2020 value amounting to $1.0 billion.

  • Lyell Immunopharma's Preferred Stock Liabilities rose 9473.04% to $1.0 billion in Q4 2020 from the same period last year, while for Dec 2020 it was $1.0 billion, marking a year-over-year increase of 9473.04%. This contributed to the annual value of $1.0 billion for FY2020, which is 9473.04% up from last year.
  • Lyell Immunopharma's Preferred Stock Liabilities amounted to $1.0 billion in Q4 2020, which was up 9473.04% from $1.0 billion recorded in Q3 2020.
  • Lyell Immunopharma's 5-year Preferred Stock Liabilities high stood at $1.0 billion for Q2 2020, and its period low was $519.2 million during Q4 2019.